Professor Carole Longson spent eight years developing novel pharmaceuticals at GlaxoSmithKline (LSE: GSK), before crossing the floor to join the UK’s national h 8 February 2017
French pharma group Ipsen’s acquisition of the oncology assets of Merrimack Pharmaceuticals (Nasdaq: MACK), which was announced in the first working week of 201 1 February 2017
Dompé chief executive Eugenio Aringhieri is realizing an ambitious plan to transform the privately owned, fully integrated company into an innovative and truly 23 January 2017
Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 sepa 16 January 2017
Lan Huang is no stranger to awards, from being named Soroptimist International’s international-level Women’s Opportunity Award in 1997 alongside her biophysical 9 January 2017
Be it in constantly improving the fundamentals of its Affimer technology.engaging with pharma partners on drug discovery programs or developing its own therapeu 11 December 2016
Roman Ivanov, vice president of research and development (R&D) at Biocad, describes his company’s current transition as going from being a local biosimilar play 29 November 2016
Guido Rasi, executive director of the European Medicines Agency (EMA), has seen some huge steps being taken by the regulator since he first took on the role in 21 November 2016
The promise being shown by plinabulin, not just as a natural compound that could provide multiple potential therapeutic benefits in a variety of cancers but als 16 November 2016
Immuno-oncology company PsiOxus Therapeutics may opt for an initial share in 2017, though the company is not looking to go public anytime sooner, Chief Executiv 4 November 2016
Cham Herath, the medical director at Italian drugmaker Chiesi Farmaceutici, knew that news of his company’s progress this month with a first-of-its-kind triple 3 October 2016
Thierry Diagnana, head of the Novartis Institutue for Tropical Diseases (NITD), speaks to the Pharma Letter’s Katie Osborne about a new anti-malarial molecule, 23 September 2016
British-born Christian Hogg can say with some confidence that the milestone of a Chinese company taking a drug candidate from discovery all the way to global re 19 September 2016
The discussion about anti-infective products and drug-resistant pathogens has become one of the biggest issues in health care internationally. 12 September 2016
Ajan Reginald does not dispute the ability of life-saving cellular therapies to reach patients – and backs regulators’ moves to make this happen quicker through 30 August 2016
The use of esketamine as a treatment for major depressive disorder (MDD) could transform the treatment landscape and prevent thousands of people from taking the 20 August 2016
At a time when the inability of UK patients to access certain potentially lifesaving cancer drugs has come under fire, one company executive has praised the sta 17 August 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.